ReviewReproductive sciences (Thousand Oaks, Calif.)2025
Circulating Cell Free microRNAs in Women with Polycystic Ovary Syndrome: Advancing Towards Biomarker Discovery and Therapeutic Targets.
Review in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Polycystic ovary syndrome (PCOS) is the most common metabolic and endocrine disorder affecting women of reproductive age. This condition is characterized by the presence of polycystic ovarian morphology, anovulation, and clinical or biochemical manifestations of hyperandrogenism. Numerous patients diagnosed with PCOS also experience conditions such as obesity, hirsutism, insulin resistance, and an elevated risk of developing type 2 diabetes, dyslipidemia, hypertension, cardiovascular disease, endometrial cancer, as well as infertility and complications during pregnancy. While the precise etiology remains unidentified, it is widely acknowledged that genetic, environmental, and epigenetic factors contribute to the pathogenesis of PCOS. This review consolidates findings from various studies that investigated circulating microRNAs (miRNAs) as potential diagnostic biomarkers for PCOS, illustrating both their promise and the challenges associated with clinical implementation. We address the obstacles pertaining to standardization, explore the diagnostic potential of statistically significant miRNAs across multiple biofluids, including plasma, serum, follicular fluid, and blood, and present a graphical overview of overlapping miRNAs accompanied by a table summarizing key findings. With further validation, miRNAs hold the potential not only to improve the diagnostic processes for PCOS but also to facilitate the development of novel therapeutic interventions for the management of this disorder.
Indexed as
Identifiers
40439880What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.